IDXX · 8-K · 20260804PR090033

Guidance and Outlook

IDEXX LABORATORIES INC /DE · 2026-08-04 · Importance 80 · Surprise 68 · In source text

IDEXX narrowed 2026 revenue guidance to $4,700 million-$4,745 million, with reported growth of 9.1%-10.3% and organic growth of 8.5%-9.7%. The midpoint increased by $5 million, despite a projected $15 million revenue headwind from a stronger U.S. dollar. The company raised its operating-margin outlook to 32.3%-32.5% and EPS outlook to $14.69-$14.94, with the EPS midpoint increasing $0.14 from prior guidance. CAG Diagnostics recurring-revenue growth is projected at 10.1%-11.3% reported and 9.5%-10.7% organic.

Key facts

IDEXX narrowed 2026 revenue guidance to $4,700 million - $4,745 million, up $5 million at midpoint net of a $15 million foreign exchange reduction. source
Company raised midpoint for 2026 reported revenue growth outlook to 9.7%, reflecting a range of 9.1% - 10.3%. source
Projected 2026 organic revenue growth: 8.5% - 9.7%. source
Updated 2026 EPS outlook: $14.69 - $14.94, reflecting an increase of $0.14 compared to prior guidance midpoint. source
Operating cash flow as percentage of net income projected for 2026: 110% - 120% (updated) versus prior 105% - 115%. source

Impact estimates

metric	direction	stage	expected	basis
revenue	positive	committed	+0.3%	IDEXX narrowed 2026 revenue guidance to $4,700 million - $4,745 million, up $5 million at midpoint net of a $15 million foreign exchange…
revenue	positive	committed	—	Company raised midpoint for 2026 reported revenue growth outlook to 9.7%, reflecting a range of 9.1% - 10.3%.
revenue	positive	committed	—	Projected 2026 organic revenue growth: 8.5% - 9.7%.
net_income	positive	committed	—	Updated 2026 EPS outlook: $14.69 - $14.94, reflecting an increase of $0.14 compared to prior guidance midpoint.
cash	positive	committed	—	Operating cash flow as percentage of net income projected for 2026: 110% - 120% (updated) versus prior 105% - 115%.